LyoWave

LyoWave is a private, pre-revenue platform technology company focused on the drug delivery and manufacturing sector. Its core innovation is the application of tunable, high-frequency microwave heating to the traditional freeze-drying process, which promises to significantly reduce processing times from days/weeks while enhancing product quality and uniformity. The company has licensed foundational technology from Purdue University, secured non-dilutive grant funding (including an NSF SBIR Phase I award), and entered a strategic collaboration with equipment manufacturer Millrock Technology to commercialize its solution. LyoWave's technology targets a critical bottleneck in the manufacturing of thermally sensitive pharmaceuticals, including vaccines and biologics, aiming to create a more stable and efficient global supply chain.

Tunable high-frequency microwave heating technology designed to accelerate, improve uniformity, and increase energy efficiency of the pharmaceutical freeze-drying (lyophilization) process. Compatible with existing equipment from benchtop to commercial scale.

LyoWave competes in the pharmaceutical lyophilization equipment and services market, dominated by large players like SP Scientific, GEA, and IMA. Its primary competition is the entrenched standard of conventional conductive/radiative freeze-drying. It may also face future competition from other advanced drying technologies (e.g., spray drying, controlled nucleation) and from internal R&D efforts by large manufacturers to improve their own systems.